Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | What we still don’t know about the RATIFY study of midostaurin in AML

Richard Stone • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin Midostaurin
RATIFY

The Phase III RATIFY study (NCT00651261) investigated daunorubicin, cytarabine and the FLT3 inhibitor midostaurin for the treatment of newly diagnosed acute myeloid leukemia (AML). Here, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the questions remaining from this trial, speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Richard Stone

Evaluating the use of MRD status to guide post-remission therapy in AML
1:20
Evaluating the use of MRD status to guide post-remission therapy in AML
Richard Stone • 28 Feb 2026
The safety and efficacy of adding venetoclax to intensive chemotherapy for patients with AML
1:40
The safety and efficacy of adding venetoclax to intensive chemotherapy for patients with AML
Richard Stone • 28 Feb 2026
Approaches to managing FLT3-mutant AML
12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025
Novel targets, treatments, and combinations in AML
Novel targets, treatments, and combinations in AML
David Sallman et al. • 29 Sep 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals